The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.
2021
Details
Title
The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.
Author(s)
Wullschleger, Stephan ; Tichet, Melanie ; Codarri-Deak, Laura ; Umana, Pablo ; Klein, Christian ; Hanahan, Douglas
Published in
Cancer Research
Volume
81
Issue
13
Date
2021-07-01
Publisher
Philadelphia, AMER ASSOC CANCER RESEARCH
ISSN
0008-5472
1538-7445
1538-7445
Other identifier(s)
View record in Web of Science
Laboratories
CMSO
Record Appears in
Scientific production and competences > SV - School of Life Sciences > ISREC - Swiss Institute for Experimental Cancer Research > CMSO - Merck Serono Chair in Oncology
Peer-reviewed publications
Conference Papers
Work produced at EPFL
Published
Peer-reviewed publications
Conference Papers
Work produced at EPFL
Published
Record creation date
2021-09-11